spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Pharming Group 

 HSMN NewsFeed - 20 Jul 2021
Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST(R) in the Middle East and North Africa
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 13 Nov 2018
HOX Therapeutics Appoints Karl Keegan as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jan 2018
Pharming Announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST(R) for Prophylaxis of Hereditary Angioedema Attacks
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Nov 2017
Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST(R) for Prophylaxis of Hereditary Angioedema Attacks
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2017
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Dec 2016
Pharming Announces Completion of Acquisition of All North American Commercialisation Rights for RUCONEST(R) From Valeant
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 11 Nov 2016
CHMP Adopts Positive Opinion to Include Self-administration for RUCONEST(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Apr 2016
Pharming Announces Adoption by the European Commission of the CHMP Recommendation to Change the Terms of the Marketing Authorisation for Ruconest(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Aug 2015
Regulus Appoints Michael Huang, M.D. as Vice President, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Nov 2014
Salix and Pharming Announce the Launch of RUCONEST(R) in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 17 Jul 2014
Salix and Pharming Announce FDA Approval of RUCONEST(R) for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Feb 2013
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 10 Apr 2012
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2012
Santarus Announces FDA Acceptance of UCERIS New Drug Application for Induction of Remission of Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 13 Feb 2012
Santarus Announces Initiation of Phase IIIb Study with UCERIS in Patients with Mild or Moderate Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Feb 2012
Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2011
Santarus and Pharming Announce Receipt of FDA Refusal to File Letter for RHUCIN Biologics License Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Feb 2011
Santarus and Pharming Announce Initiation of Phase IIIb Clinical Study with RHUCIN in Acute Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 28 Dec 2010
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
Biopharmaceuticals
 HSMN NewsFeed - 28 Dec 2010
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 5 Oct 2010
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
Biopharmaceuticals
 HSMN NewsFeed - 13 Sep 2010
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
Biopharmaceuticals
 HSMN NewsFeed - 27 Apr 2009
Prodarsan(R) granted Orphan Drug designation from FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Mar 2008
Pharming signs distribution agreement for Rhucin(R) in Turkey
Biopharmaceuticals Distribution
 HSMN NewsFeed - 20 Mar 2008
Pharming to receive Negative Opinion on European Marketing Authorization Application for Rhucin(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Aug 2007
Pharming Presents Positive Results from European Phase III Trial of Rhucin(R)
Biopharmaceuticals
 HSMN NewsFeed - 29 Mar 2007
Pharming Strengthens Organization for Commercial Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2007
Pharming Receives European Orphan Drug Designation
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Nov 2006
Pharming Shareholders Appoint Bruno Giannetti as Member of the Board of Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Sep 2006
Pharming Appoints Bruno Giannetti as Chief Operations Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jul 2006
Pharming Submits Marketing Authorisation Application for Recombinant Human C1 Inhibitor in Europe
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
Pharming Group
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.